Essentials · Evidence reviewed
Can treatment build on weight lost before starting medication?
Many people begin medication only after already making major lifestyle changes. The SURMOUNT-3 trial addressed this specific situation: researchers studied tirzepatide after participants had completed a 12-week intensive lifestyle program and lost at least 5% of their starting weight.
How was the study designed?
During a 12-week lifestyle lead-in, 806 participants began the program. Of those, 579 who lost at least 5% of body weight and met the remaining criteria were randomized to tirzepatide or placebo for 72 weeks. This selected group is important when interpreting results.
How much had participants lost before medication?
Participants who were randomized had reduced body weight by an average of about 6.9% during the lead-in. This figure is measured before the randomized medication comparison began.
What happened after starting tirzepatide?
From randomization to week 72, the tirzepatide group had an additional average weight change of −18.4%, compared with +2.5% in the placebo group, based on the study's treatment-regimen analysis. These percentages refer to weight at randomization, not the original pre-lifestyle starting weight.
What does this result not prove?
It does not mean every person should complete a rigid 12-week program before seeking care, nor does it predict the response of someone who did not meet the study's entry criteria. It also isn't a comparison between tirzepatide and every other drug.
How can readers use the evidence?
Tell your prescriber what lifestyle measures and weight changes you have already achieved. It may help set goals and choose a plan that builds on existing progress rather than restarting from zero.
The bottom line
Previous lifestyle success and later medication benefit can complement each other, but trial eligibility limits how broadly averages apply.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2023-10-15. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceAdditional evidenceThis guide explains published evidence; source dates may be older than the review date. Our interpretation is educational and does not replace medical or insurance advice.